Sana Biotechnology's cash burn versus its market cap is worrisome. Despite a notable decrease in its cash burn, the potential need for more funding via new shares could result in costly shareholder dilution.
Gainers: •$リペア・セラピューティクス(RPTX.US)$+26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib) •$チューイ A(CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered) •$ユーアイパス(PATH.US)$+11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million) •$ピュア ストレージ A(PSTG.US)$+10.6% (In reaction to earnings) •$クレド テクノロジー グループ(CRDO.US)$+10.2% (In reaction ...
$ビーム・セラピューティクス(BEAM.US)$$サナバイオテクノロジー(SANA.US)$ SANA announced an initial payment of 50M using Beam's Cas12b system. It's great for Beam that Cas12b, which Beam doesn't use, is being asked for. The strangest thing is that SANA only needs Cas12b, not Base Editor. It's hard to understand! ?
サナバイオテクノロジーに関するコメント
• Editing Genes | $CRISPRセラピューティクス(CRSP.US)$ , $インテリア セラピューティクス(NTLA.US)$ , $ビーム・セラピューティクス(BEAM.US)$ , $ヴァーヴ セラ(VERV.US)$ , $エディタス メディシン(EDIT.US)$
• Creating Therapies | $プライム・メディスン(PRME.US)$ , $サナバイオテクノロジー(SANA.US)$
• Building DNA | $ツイスト バイオサイエンス(TWST.US)$ , $ギンコ バイオワークス ホールディングス A(DNA.US)$ , $パシフィックバイオサイエンシズオブカリフ(PACB.US)$ , $イルミナ(ILMN.US)$
• Dis...
• $リペア・セラピューティクス(RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $チューイ A(CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $ユーアイパス(PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $ピュア ストレージ A(PSTG.US)$ +10.6% (In reaction to earnings)
• $クレド テクノロジー グループ(CRDO.US)$ +10.2% (In reaction ...
SANA announced an initial payment of 50M using Beam's Cas12b system.
It's great for Beam that Cas12b, which Beam doesn't use, is being asked for. The strangest thing is that SANA only needs Cas12b, not Base Editor. It's hard to understand! ?
まだコメントはありません